## Clinical Context ASCUS with high-risk HPV positivity carries a 20–30% risk of underlying CIN 2/3 or invasive disease and mandates immediate colposcopic evaluation. ## Management Algorithm for ASCUS + HR-HPV **Key Point:** ASCUS + HR-HPV positive = colposcopy is mandatory; reflex HPV testing has replaced repeat cytology as the standard of care in most guidelines. **High-Yield:** The 2019 ASCCP guidelines recommend colposcopy for all ASCUS cases with positive HR-HPV testing, regardless of age (with rare exceptions in women <25 years). ## Why Colposcopy? 1. Allows direct visualization of the cervix under magnification (×6–40×). 2. Enables targeted biopsy of acetowhite, punctate, or mosaic lesions. 3. Histology confirms grade of CIN (CIN 1, CIN 2, CIN 3) and guides definitive treatment. ## Typical Colposcopy Findings in CIN | Feature | CIN 1 | CIN 2/3 | |---------|-------|--------| | Acetowhitening | Faint, thin | Dense, thick | | Margins | Feathered | Sharp, distinct | | Vascular pattern | Fine punctation | Coarse punctation/mosaic | | Iodine uptake (Schiller) | Partial | Absent | **Clinical Pearl:** HR-HPV positivity alone does NOT diagnose CIN; histology is the gold standard. Colposcopy bridges cytology and histology. ## Why Not the Other Options? - **Repeat Pap in 12 months:** Delays diagnosis in a high-risk patient; reflex HPV testing has made this obsolete. - **LEEP without colposcopy:** Inappropriate; LEEP is a treatment, not a diagnostic tool. Biopsy-proven CIN 2/3 is the indication for LEEP. - **Hysterectomy:** Grossly over-treatment for a screening abnormality; reserved only for invasive cancer or recurrent CIN after multiple treatments. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.